<DOC>
	<DOCNO>NCT01118949</DOCNO>
	<brief_summary>The purpose ass safety Lacosamide subject uncontrolled Primary Generalized Tonic-Clonic ( PGTC ) seizures Idiopathic Generalized Epilepsy .</brief_summary>
	<brief_title>Open-Label Study Assess Lacosamide Safety Add-on Therapy Primary Generalized Tonic-Clonic Seizures Subjects With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject diagnosis uncontrolled epilepsy primary generalize tonicclonic ( PGTC ) seizures idiopathic generalize epilepsy . Diagnosis establish electroencephalogram ( EEG ) generalize spikewave discharge within 5 year screen visit Subject â‰¥1 PGTC seizure within 12 week prior screen visit Subject stable dose regimen 1 3 market antiepileptic drug ( ) ( AEDs ) without additional concurrent stable Vagus Nerve Stimulation ( VNS ) . The VNS must place least 6 month prior study entry constant setting least 28 day prior screen visit Baseline Phase . Benzodiazepines count AED Subject history partialonset seizures EEG finding consistent partial onset seizure Subject history status epilepticus within 5year Period prior Visit 1 Subject current previous diagnosis pseudoseizures , conversion disorder , nonepileptic ictal event Subject medical psychiatric condition Subject history alcohol drug abuse Subject currently take felbamate Subject ever take vigabatrin visual field examination report available result examination abnormal Subject ketogenic diet Subject know sodium channelopathy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Primary Generalized Tonic-Clonic ( PGTC ) Seizures</keyword>
	<keyword>Absence Seizures</keyword>
	<keyword>Myoclonic Seizures</keyword>
	<keyword>Idiopathic Generalized Epilepsy ( IGE )</keyword>
</DOC>